A pilot observational crossover study of QTc interval changes associated with switching between olanzapine and risperidone [8]

Journal of Clinical Psychiatry

Volumn 68, Issue 5, 2007, Pages 803-805

  Huang, Chieh Liang ^a   Su, Kuan Pin ^a   Hsu, Hsiu Bao ^a   Pariante, Carmine M ^b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE;

ADULT; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG SUBSTITUTION; ELECTROCARDIOGRAM; FEMALE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; QT INTERVAL; SCHIZOPHRENIA; SCORING SYSTEM; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CROSSOVER PROCEDURE; ELECTROCARDIOGRAPHY; LONG QT SYNDROME; MIDDLE AGED;

ADULT; BENZODIAZEPINES; CROSS-OVER STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA;

EID: 34249692098     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v68n0522g     Document Type: Letter

References (21)

1. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-1782
2. Shen WW, Su KP. Torsadogenicity and antipsychotic drugs. Taiwan J Psychiatry 2000;14:6-22
3. Su KP, Chang HC, Shen WW. Prolongation of QTc interval and antipsychotics. Am J Psychiatry 2002;159:1062-1063
4. Tan HL, Hou CJ, Lauer MR, et al. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med 1995;122:701-714
5. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441-448
6. Czekalla J, Beasley CM Jr, Dellva MA, et al. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatry 2001;62:191-198
7. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005;66:63-72
8. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-69
9. Ravin DS, Levenson JW. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 1997;31:867-870
10. Duenas-Laita A, Castro-Villamor MA, Martin-Escudero JC, et al. New clinical manifestations of acute risperidone poisoning. J Toxicol Clin Toxicol 1999;37:893-895
11. Lee HS, Tan CH, Au LS, et al. Serum and urine risperidone concentrations in an acute overdose. J Clin Psychopharmacol 1997;17:325-326
12. Yerrabolu M, Prabhudesai S, Tawam M, et al. Effect of risperidone on QT interval and QT dispersion in the elderly. Heart Dis 2000;2:10-12
13. Drolet B, Yang T, Daleau P, et al. Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharmacol 2003;41:934-937
14. Titier K, Canal M, Deridet E, et al. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol 2004;199:52-60
15. Kongsamut S, Kang J, Chen XL, et al. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 2002;450:37-41
16. Su KP, Wu PL, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology (Berl) 2005;183:383-386
17. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Welfare, and Education (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
18. International Diabetes Federation. IDF Consensus Worldwide Definition of the Metabolic Syndrome. Available at: http://www.idf.org/webdata/docs/ IDF_metasyndrome_definition.pdf. Accessed July 1, 2005
19. Bazett HC. An analysis of the time relations of electrocardiograms. Heart 1920;7:353-367
20. Su KP, Shen WW, Chuang CL, et al. A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol. Schizophr Res 2003;59:93-94
21. Malik M, Hnatkova K, Batchvarov V, et al. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation. Pacing Clin Electrophysiol 2004;27:1659-1669